Signatera™ is a highly sensitive and personalized MRD assay using ctDNA and is custom designed for each patient to help identify relapse earlier than standard of care tools

Signatera is a new blood test that can identify molecular residual disease (MRD), or recurrent cancer, sooner than existing methods by detecting the presence of circulating tumor DNA …

May 28, 2025 · Background: Circulating tumor DNA (ctDNA) has emerged as a powerful, minimally invasive biomarker of treatment response and pt prognosis. Signatera, a tumor …

Apr 24, 2025 · Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses …

Jul 23, 2025 · Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously …

Nov 21, 2025 · The Signatera™ measures ctDNA, a type of cell-free DNA that can be detected and measured in the body’s circulatory system. Accurate identification of ctDNA in the body …

Signatera sequences the tumour tissue to identify the person's unique signature of tumour mutations. This is used to design a multiplex polymerase chain reaction (PCR) assay targeting …

SignateraTM is a custom-designed MRD test that is based on each patient’s unique set of tumour mutations. Knowing earlier if your cancer is likely to recur or has progressed after treatment …

Signatera test detects presence or absence of tumor DNA Once your personalized Signatera test is created, it can be used to detect the presence or absence of tumor DNA from any future …

Test Information: Signatera™ is a mPCR-NGS assay for detection and quantification of circulating tumor DNA (ctDNA) in the plasma of patients previously diagnosed with cancer. Individual …